Research Article
No access
Published Online: 20 April 2005

A Novel Approach to Continuous Glucose Analysis Utilizing Glycemic Variation

Publication: Diabetes Technology & Therapeutics
Volume 7, Issue Number 2

Abstract

Background: Various methodologies have been proposed for analysis of continuous glucose measurements. These methods have mainly focused on the proportion of low or high glucose readings and have not attempted to analyze other dimensions of the data obtained. This study proposes an algorithm for analysis of continuous glucose data including a novel method of assessing glycemic variability.
Methods: Mean blood glucose and mean of daily differences (MODD) assessed the degree that the Continuous Glucose Monitoring System (CGMS®, Medtronic MiniMed, Northridge, CA) trace was representative of the 3-month glycemic pattern. Percentages of times in low, normal, and high glucose ranges were used to assess marked glycemic excursion. Continuous overall net glycemic action (CONGA), a novel method developed by the authors, assessed intra-day glycemic variability. These methods were applied to 10 CGMS traces chosen randomly from those completed by children with type 1 diabetes from the Royal Children's Hospital, Melbourne, Victoria, Australia and 10 traces recorded by healthy volunteer controls.
Results: The healthy controls had lower values for mean blood glucose, MODD, and CONGA. Patients with diabetes had higher percentages of time spent in high and low glucose ranges. There was no overlap between the CONGA values for patients with diabetes and for controls, and the difference between controls and patients with diabetes increased markedly as the CONGA time period increased.
Conclusions: We advocate an approach to the analysis of CGMS data based upon a hierarchy of relevant clinical questions alluding to the representative nature of the data, the amount of time spent in glycemic excursions, and the degree of glycemic variation. Integrated use of these algorithms distinguishes between various patterns of glycemic control in those with and without diabetes.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

cover image Diabetes Technology & Therapeutics
Diabetes Technology & Therapeutics
Volume 7Issue Number 2April 2005
Pages: 253 - 263
PubMed: 15857227

History

Published online: 20 April 2005
Published in print: April 2005

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

C.M. McDonnell
Centre for Hormone Research, Royal Children's Hospital, Parkville, Melbourne, Victoria, Australia.
Novo Nordisk Clinical Research Fellow.
S.M. Donath
Clinical Epidemiology and Biostatistics Unit, Royal Children's Hospital, Parkville, Melbourne, Victoria, Australia.
S.I. Vidmar
Clinical Epidemiology and Biostatistics Unit, Royal Children's Hospital, Parkville, Melbourne, Victoria, Australia.
G.A. Werther
Centre for Hormone Research, Royal Children's Hospital, Parkville, Melbourne, Victoria, Australia.
F.J. Cameron
Centre for Hormone Research, Royal Children's Hospital, Parkville, Melbourne, Victoria, Australia.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top